SEC Form 4 · accession 0001144204-17-012785
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arturo Araya
Director
Period of report
Feb 26, 2017
Accepted (ET)
Mar 3, 2017 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 26, 2017 | A | 3,012 | $0.00 | A | 3,012 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired are shares of restricted stock awarded on February 26, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 26, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.